Kura Oncology, Inc. (KURA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Kura Oncology (KURA) Q1 2026: ComSifty Captures 40% New Patient Share, Accelerating Class Leadership
  May 13, 2026
• KURA Q4 2025: ComSifty Launch Drives $2.1M Revenue, Step-Edit Access Signals Class Leadership Shift
  March 05, 2026
• Kura Oncology (KURA) Q3 2025: $105M Milestone Inflow Accelerates Ziftomenib Launch Readiness
  November 04, 2025
• Kura Oncology (KURA) Q2 2025: $630M Cash Anchors Zipdementib Launch and Phase III Acceleration
  August 08, 2025
• Kura Oncology (KURA) Q1 2025: Cash Position Rises to $703M, Pipeline Momentum Sets Up Multi-Asset Inflection
  July 04, 2025

Browse all companies